Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $40.5152W HIGH $59.68
Volume
182.25 K
Value Traded
35.88 M
Short % Float
9.15%
+1.04%Week
+1.78%1 Month
-11.64%3 Month
-15.51%6 Month
+53.19%5 Year
+641.69%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.50 B
EPS (TTM)
-1.89
P/E Ratio
-
Ent. Value
2.12 B
Total Shares
58.22 M
Float Shares
54.53 M
Insiders
6.34%
Institutions
102.41%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
SUPN Catalyst Timeline
Dated clinical, regulatory and corporate events for Supernus Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Supernus Pharmaceuticals, Inc.
666Total events
9Upcoming
168Tier-1 (high impact)
2012 to 2027Coverage
Upcoming catalysts 2
Event history 50
●Quarterly UpdateCorporate
Q2 2026 financial results to be reported in separate press releases
▲Quarterly UpdateCorporate
Approximately 3 million prescriptions filled since launch, over 1 million in 2025
●NDA SubmissionOnapgo (SPN-830)ApprovedRegulatory Filing
Regulatory submission to FDA for second supplier for ONAPGO
◆Milestone PaymentZURZUVAECorporate
CVR milestone: first commercial sale in Japan for MDD after regulatory approval by June 30, 2026
major depressive disordersource ↗
◆Other Regulator MilestoneZURZUVAEEx-US Regulatory
First commercial sale after regulatory approval in Japan for ZURZUVAE in MDD
Major Depressive Disordersource ↗
◆Product LaunchZURZUVAEPost-Market
First commercial sale of ZURZUVAE in Japan for MDD
Major Depressive Disordersource ↗
◆Oral PresentationPresentation
Supernus management to participate in Goldman Sachs 47th Annual Global Healthcare Conference
◆Oral PresentationPresentation
Supernus management to participate in Jefferies Global Healthcare Conference fireside chat
◆Oral PresentationPresentation
Supernus Pharmaceuticals to participate in fireside chat at Bank of America 2026 Health Care Conference
◆Oral PresentationPresentation
Barclays 28th Annual Global Healthcare Conference Fireside Chat
◆Oral PresentationPresentation
Supernus Pharmaceuticals presentation at Bank of America Securities 2025 CNS Therapeutics Virtual Conference
◆Oral PresentationPresentation
Supernus Pharmaceuticals to participate in Piper Sandler 37th Annual Healthcare Conference fireside chat
◆Oral PresentationPresentation
Supernus participates in fireside chat at 2025 Jefferies Global Healthcare Conference in London
◆Oral PresentationPresentation
TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit fireside chat
◆Oral PresentationPresentation
Supernus participates in 2025 Jefferies Global Healthcare Conference fireside chat
◆Para Iv CertificationQelbreeApprovedIP / Competition
Paragraph IV ANDA filings for Qelbree received
ADHDsource ↗
◆Oral PresentationQelbreeApprovedPresentation
Topline results from full Phase IV trial to be presented at APA Annual Meeting
ADHD with mood symptomssource ↗
▲Product LaunchOnapgo (SPN-830)ApprovedPost-Market
ONAPGO launched in the U.S.
motor fluctuations in adults with advanced Parkinson's diseasesource ↗
◆Oral PresentationPresentation
Supernus participates in TD Cowen 45th Annual Health Care Conference
▼Primary Endpoint MissedSPN-820Clinical Data
Phase 2b study of SPN-820 in TRD did not meet primary endpoint
treatment-resistant depressionsource ↗
▲FDA ApprovalOnapgo (SPN-830)ApprovedFDA Decision
FDA approval of ONAPGO for motor fluctuations in advanced Parkinson's disease
Parkinson's diseasesource ↗
◆PDUFA DateSPN-830FiledRegulatory Filing
PDUFA date for SPN-830 set to February 1, 2025
Parkinson's disease motor fluctuationssource ↗
▲FDA ApprovalOnapgo (SPN-830)ApprovedFDA Decision
FDA approval of ONAPGO (apomorphine hydrochloride) for motor fluctuations in advanced PD
Parkinson's diseasesource ↗
▲Label ExpansionQelbreeApprovedFDA Decision
FDA approval of Qelbree label update including pharmacodynamic and lactation data
ADHDsource ↗
▲Patent GrantedQelbreeApprovedIP / Competition
Patent term extension for US Patent No. 9,662,338 covering Qelbree to 2035
ADHDsource ↗
▲Interim AnalysisQelbreeApprovedTrial
Interim results from open-label Phase IV trial in adults with ADHD and mood symptoms presented at conference
ADHD with mood symptomssource ↗
▲Trial InitiationSPN-817, Treatment BTrial
Initiation of Phase 2b randomized double-blind placebo-controlled study of SPN-817
treatment-resistant focal seizuressource ↗
▼Topline ReadoutSPN-820Clinical Data
Topline results from Phase 2b study of SPN-820 in TRD
treatment-resistant depressionsource ↗
Past FDA Catalysts and PDUFA Decisions
How SUPN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-06-30 | SPN-820 | Phase 2b topline data readout | Phase 2b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
B62 / 100
Pipeline Score
$4.6B
Pipeline Value
$3.6B
Commercial Value
Undervalued
Valuation Signal
12
Drugs Scored
6.3x
rNPV / MCap
Top 6%
Small Cap(rank 40 of 658)
Percentile Rank
Supernus Pharmaceuticals, Inc. holds a solid B-grade pipeline (62/100), with $7.1B risk-adjusted pipeline value, led by ADS-5102 in Multiple Sclerosis (Phase 3), across $175B in total addressable markets.
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $830.4M x 4.4 = $3.6B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Qelbree | $329M | $279M | +18.1% |
| GOCOVRI | $152M | $140M | +8.8% |
| ONAPGO | $38M | - | - |
| Trokendi XR | $36M | $54M | -32.9% |
| Oxtellar XR | $35M | $65M | -45.9% |
| APOKYN | $34M | $68M | -49.8% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every SUPN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| SPN-820 | treatment-resistant depression | Phase 2b | 2025-02-18 | SPN-820 LS mean Standard Error -12.3 0.96 vs. placebo -11.9 0.96 p not significantRead More | Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptomsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Rubin JonathanOfficer (SVP, Chief Medical Officer) | Option | 750 14,342 held | $0.00 | 08/12/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SUPN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Sofinnova Investments, Inc. | 2.5 % (31.6 %) | 48.20 M | 1.04 M | 8.59% ( 82.02 K) |
SUPN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SUPN ranks across every disease it competes in
Competitive Position is a premium feature
See how SUPN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSUPN News
SUPNSupernus Pharmaceuticals to Participate in September Investor Conferences
Supernus Pharmaceuticals announced its participation in several investor conferences in September. The company focuses on developing treatments for central nervous system diseases and offers a range of approved products. Investors can arrange meetings with management and access live webcasts of the conferences on the company's website.
Read more →SUPNChloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD
Chloe Kim is collaborating with Supernus to raise awareness about ADHD in adults. The initiative emphasizes the importance of recognizing symptoms that often persist from childhood into adulthood. By encouraging individuals to work with their healthcare providers, the campaign aims to promote personalized treatment plans for managing ADHD effectively.
Read more →SUPNSupernus Announces Second Quarter 2026 Financial Results
Supernus Pharmaceuticals reported a 32% increase in total revenues for Q2 2026, driven by strong sales of its growth products. The company is on track with its regulatory submission for ONAPGO's second supplier and has raised its full-year financial guidance. Additionally, Supernus announced a merger with Indivior Pharmaceuticals, aiming to create a larger CNS biopharmaceutical entity. Despite these positive developments, the company recorded an operating loss and a significant net loss for the quarter.
Read more →SUPNSupernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
Supernus Pharmaceuticals and Indivior Pharmaceuticals have announced a merger to create a leading CNS biopharmaceutical company. The combined entity, named Supernus, Inc., is expected to generate significant cost synergies and enhance financial flexibility. Jack Khattar will lead the new company, which will have a diverse portfolio of CNS medicines and a strong financial profile. The merger is anticipated to close in Q4 2026, pending regulatory approvals.
Read more →SUPNSupernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026
Supernus Pharmaceuticals will announce its second quarter 2026 financial results on August 4, 2026, after market close. A conference call will follow at 4:30 p.m. ET, hosted by CEO Jack Khattar and CFO Tim Dec. The call will allow for investor questions and will be available for replay on the company's website.
Read more →SUPNSupernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD
Supernus Pharmaceuticals celebrates the five-year anniversary of Qelbree's FDA approval for ADHD. Qelbree is notable as the first non-stimulant ADHD medication approved in over a decade, with over 3 million prescriptions filled. The drug has expanded its indications to include adults and has received updates to its labeling, enhancing its pharmacodynamic profile. Supernus emphasizes the importance of flexible treatment options for ADHD management.
Read more →SUPNSupernus Expands Partnership With MERGE as AI-Powered Agency of Record
Supernus Pharmaceuticals has expanded its partnership with MERGE, selecting them as the Agency of Record (AOR). This collaboration aims to enhance digital marketing strategies using AI-driven data and technology solutions, focusing on personalized communication for both existing and new products, including QELBREE for ADHD. The expanded partnership illustrates a strong, trust-based relationship developed over seven years and signifies a commitment to innovative healthcare communication experiences. MERGE will manage Supernus's digital ecosystem, supporting their portfolio in CNS diseases.
Read more →SUPNSupernus Pharmaceuticals to Participate in June Investor Conferences
Supernus Pharmaceuticals, Inc. announced its participation in several investor conferences in June. Investors can arrange meetings with management during these events. A live audio webcast of the Jefferies Global Healthcare Conference will be available on the company's website, along with archived replays for 60 days post-conference. The company focuses on CNS disease treatments.
Read more →SUPNSupernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
Supernus Pharmaceuticals will participate in the Bank of America 2026 Health Care Conference on May 12, 2026. CEO Jack A. Khattar will lead a fireside chat at the event. Investors can arrange meetings with management and access a live audio webcast of the presentation. The company focuses on CNS disease treatments.
Read more →SUPNSupernus Announces First Quarter 2026 Financial Results
Supernus Pharmaceuticals reported strong financial results for Q1 2026, with total revenues of $207.7 million, a 39% increase from the previous year. The company's growth products saw a 56% revenue increase, driven by Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO. A regulatory submission for a second supplier of ONAPGO is anticipated in Q3 2026, with potential approval by mid-2027. Despite an operating loss, the company maintains a positive outlook for the year.
Read more →SUPNSupernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026
Supernus Pharmaceuticals will report its first quarter 2026 financial results on May 5, 2026, after market close. A conference call will follow at 4:30 p.m. ET, hosted by CEO Jack Khattar and CFO Tim Dec. The call will allow for questions after their prepared remarks. A replay will be available on their Investor Relations website.
Read more →SUPN▲ +5.7%on this news
Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results
Supernus Pharmaceuticals reported record financial results for Q4 and full year 2025, highlighting significant revenue growth and strategic advancements. The company successfully acquired Sage Therapeutics and received FDA approval for ONAPGO, a treatment for Parkinson's disease. Looking ahead, Supernus aims to continue progress on its growth products and pipeline candidates in 2026.
Read more →SUPN▲ +5.1%on this newsshared move
Supernus Pharmaceuticals to Participate in March 2026Investor Conferences
Supernus Pharmaceuticals, Inc. announced its participation in March investor conferences, providing opportunities for investors to meet with management. The company focuses on developing treatments for central nervous system diseases and has a diverse portfolio that includes several approved therapies. Live webcasts of the presentations will be available on their website.
Read more →SUPNSupernus Pharmaceuticals to Participate in March Investor Conferences
Supernus Pharmaceuticals, Inc. has announced its participation in several March investor conferences, including the TD Cowen 46th Annual Health Care Conference and the Barclays 28th Annual Global Healthcare Conference. The management will engage with investors and provide updates on the company’s developments in central nervous system (CNS) therapies. Additionally, the company emphasizes its commitment to a diverse portfolio for treating various CNS diseases, while also acknowledging potential risks associated with future business performance and regulatory approvals.
Read more →SUPNSupernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026
Supernus Pharmaceuticals, Inc. has announced that it will report its fourth quarter and full year 2025 financial results on February 24, 2026. The announcement will be followed by a conference call hosted by key executives, providing an opportunity for investors to gain insights into the company's performance and future prospects. The company's focus remains on CNS diseases, and despite its diverse portfolio, it faces various risks concerning profitability and regulatory approvals that could impact its financial outlook.
Read more →SUPNSupernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference
Supernus Pharmaceuticals will present at the Bank of America Securities 2025 CNS Therapeutics Virtual Conference on December 8, 2025. CEO Jack A. Khattar will lead the presentation, highlighting the company's focus on CNS disease treatments. Investors can access a live audio webcast and arrange meetings with management during the conference.
Read more →SUPNSupernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference
Supernus Pharmaceuticals announced that its CEO, Jack A. Khattar, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025. The event will be held in New York City and includes opportunities for investors to meet with company management. A live audio webcast will be available for those unable to attend in person, along with an archived replay following the conference. The company focuses on developing treatments for various central nervous system conditions.
Read more →SUPNSupernus to Participate in the 2025 Jefferies Global Healthcare Conference in London
Supernus Pharmaceuticals will participate in the 2025 Jefferies Global Healthcare Conference in London. CEO Jack A. Khattar will engage in a fireside chat on November 17, 2025. Investors can arrange meetings with management and access a live audio webcast of the presentation. The company focuses on CNS disease treatments and has a diverse portfolio.
Read more →SUPN▼ -17.4%on this news
Supernus Announces Third Quarter 2025 Financial Results
Supernus Pharmaceuticals reported strong financial results for Q3 2025, driven by robust sales of its growth products, including Qelbree and GOCOVRI. The company also highlighted the successful launch of ONAPGO and provided an optimistic outlook for 2026. However, it faces challenges from generic competition affecting Trokendi XR and Oxtellar XR.
Read more →SUPNSupernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
Supernus Pharmaceuticals will report its third quarter 2025 financial results on November 4, 2025. The announcement includes a conference call hosted by CEO Jack Khattar and CFO Tim Dec to discuss the results. A live webcast will be available, and participants can pre-register for the call. The company specializes in CNS disease treatments.
Read more →About Supernus Pharmaceuticals, Inc.
Headquarters9715 KEY WEST AVENUE, ROCKVILLE, MD, 20850
BIOPHARMAWATCH ELITE PLUS
Trade the next SUPN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime